Abstract: The present invention provides a noise modeling method to improve the speech recognition quality to help the recognition system perform better in real-life environments. With this method, we not only add noise to the training audio signal to simulate different environments, but we also add noise labels to the speech transcripts. Since then, the recognition model will perform better in different environments and increase the accuracy of the recognition model.

Abstract: The present invention relates to (2-ureidoacetamido)alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.

Abstract: A photo-medicine device may include a housing having: a mounting member and an application member including an aperture. An LED array having at least one LED configured to emit light through the aperture at a first wavelength and at least one LED configured to emit light through the aperture at a second wavelength may be mounted to the mounting member. The LED array may be in thermal communication with the mounting member such that the housing functions as a heat sink for the LED array. In some embodiments, the first wavelength comprises approximately 415 nm and the second wavelength comprises approximately 660 nm. In some embodiments, the housing has a heat dissipation surface area of at least three square inches per LED watt.

Abstract: The present invention relates to (2-ureidoacetamido)alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.

Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.

Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, A, X, Z, R1, o, R3, R2 and p are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.

Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification.

Abstract: A soft magnetic undercoat film, a first undercoat film, a second undercoat film, a perpendicular magnetic recording film, and a protective film are provided on a non-magnetic substrate, and the first undercoat film consists of Pt, Pd, or an alloy including at least one among these, and the second undercoat film consists of Ru or an Ru alloy.

Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, A, X, Z, R1, o, R3, R2 and p are as defined in the specification.

Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.

Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.